BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23410793)

  • 1. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.
    De Waele JJ; Danneels I; Depuydt P; Decruyenaere J; Bourgeois M; Hoste E
    Int J Antimicrob Agents; 2013 May; 41(5):434-8. PubMed ID: 23410793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy.
    Covajes C; Scolletta S; Penaccini L; Ocampos-Martinez E; Abdelhadii A; Beumier M; Jacobs F; de Backer D; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2013 Mar; 41(3):261-6. PubMed ID: 23312601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels.
    Truong J; Levkovich BJ; Padiglione AA
    Intern Med J; 2012 Jan; 42(1):23-9. PubMed ID: 22276559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?
    Udy AA; Covajes C; Taccone FS; Jacobs F; Vincent JL; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2013 Jun; 41(6):564-8. PubMed ID: 23473944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
    Jeurissen A; Sluyts I; Rutsaert R
    Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients.
    Ocampos-Martinez E; Penaccini L; Scolletta S; Abdelhadii A; Devigili A; Cianferoni S; de Backer D; Jacobs F; Cotton F; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2012 Apr; 39(4):332-7. PubMed ID: 22333933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.
    Li J; Udy AA; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2012 Jan; 39(1):69-72. PubMed ID: 22024354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
    Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
    Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
    Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
    Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy.
    Beumier M; Roberts JA; Kabtouri H; Hites M; Cotton F; Wolff F; Lipman J; Jacobs F; Vincent JL; Taccone FS
    J Antimicrob Chemother; 2013 Dec; 68(12):2859-65. PubMed ID: 23800905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented renal clearance in septic patients and implications for vancomycin optimisation.
    Baptista JP; Sousa E; Martins PJ; Pimentel JM
    Int J Antimicrob Agents; 2012 May; 39(5):420-3. PubMed ID: 22386742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration.
    Escobar L; Andresen M; Downey P; Gai MN; Regueira T; Bórquez T; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Aug; 44(2):163-7. PubMed ID: 24837847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients.
    Denetclaw TH; Dowling TC; Steinke D
    Ann Pharmacother; 2013 Dec; 47(12):1611-7. PubMed ID: 24259632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
    Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
    Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients.
    Lin H; Yeh DD; Levine AR
    Crit Care; 2016 Jul; 20(1):205. PubMed ID: 27363312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD; Goldstein FW
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intravenous administration of vancomycin in medical intensive care unit patients.
    Saugel B; Nowack MC; Hapfelmeier A; Umgelter A; Schultheiss C; Thies P; Phillip V; Eyer F; Schmid RM; Huber W
    J Crit Care; 2013 Feb; 28(1):9-13. PubMed ID: 22459156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.